Catalyst Wire Dossier Catalyst Wire Dossier

9-valent HPV recombinant vaccine

· Shanghai Bovax Biotechnology Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 9-valent HPV recombinant vaccine, covering 2022-10-28 to 2024-06-07. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females [Phase 3]

See pricing